Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 3
2019 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Leder BZ, et al. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. Lancet. 2015. PMID: 26144908 Free PMC article. Clinical Trial.
METHODS: This randomised controlled trial (DATA-Switch) is a preplanned extension of the denosumab and teriparatide administration study (DATA), in which 94 postmenopausal osteoporotic women were randomly assigned to receive 24 months of teriparatid …
METHODS: This randomised controlled trial (DATA-Switch) is a preplanned extension of the denosumab and teriparatide …
Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.
Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ. Tsai JN, et al. J Clin Densitom. 2017 Oct-Dec;20(4):507-512. doi: 10.1016/j.jocd.2017.05.007. Epub 2017 Jun 16. J Clin Densitom. 2017. PMID: 28624340 Free PMC article. Clinical Trial.
In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide (20 g daily), denosumab (60 mg every 6 mo), or both. Then, women originally assigned to 24 mo of teriparatide received 24 …
In the DATA and DATA-Switch studies, 94 postmenopausal osteoporotic women were randomized to receive 24 mo of teriparatide …
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ, Tsai JN, Jiang LA, Lee H. Leder BZ, et al. Bone. 2017 May;98:54-58. doi: 10.1016/j.bone.2017.03.006. Epub 2017 Mar 9. Bone. 2017. PMID: 28286299 Clinical Trial.
To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding …
To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional pres …
Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.
Tsai JN, Nishiyama KK, Lin D, Yuan A, Lee H, Bouxsein ML, Leder BZ. Tsai JN, et al. J Bone Miner Res. 2017 Oct;32(10):2001-2009. doi: 10.1002/jbmr.3198. Epub 2017 Aug 10. J Bone Miner Res. 2017. PMID: 28608571 Free article.
In postmenopausal osteoporosis, switching from teriparatide to denosumab results in continued bone mineral density (BMD) gains whereas switching from denosumab to teriparatide results in BMD loss. ...These findings strongly suggest that the use of t …
In postmenopausal osteoporosis, switching from teriparatide to denosumab results in continued bone mineral density (BMD) gains …